Methods-Tumour tissues from 270 primary breast cancer patients were evaluated for the expression of cathepsin D using inimunohistochemistry (IH; paraffin embedded tissues) and an immunoradiometric assay (IRMA; cytosol from frozen tissues). Immunohistochemical scores were based on immunoreaction in tumour cells and tumour associated macrophages. On multivariate analysis in the node negative group, IH detection of cathepsin D appeared to be the only independent factor indicating prognosis. For node positive patients, tumour grade, size, and receptor status were of prognostic relevance. Conclusions-Because of the simple methodology and the minimal amount of tissue used for analysis, immunohistochemistry was preferred to immunoradiometry for cathepsin D measurement; it also provided more predictive data with respect to prognosis.
Proteases are involved in neoangiogenesis, invasive growth, and metastasis of carcinomas. [1] [2] [3] The overexpression of the lysosomal protease cathepsin D is currently being investigated as a prognostic marker in node negative breast cancer patients.4
In 1979 Westley and Rochefort ' Immunoreactivity of tumour stroma (reaction = R) was evaluated on a four point scale ranging from 0 to 3 (0 =no positive stromal cells; 1 = single stromal cells stained; 2 = combined staining of several stromal cells; 3= strong reaction). In order to find the most appropriate method of assessing immunohistochemical measurements of cathepsin D, tumours were qualitatively characterised as positive or negative using different cut off levels and varying combinations of immunoreactivity in tumour cells and stroma (table 1) . These results were individually compared with the results of the immunoradiometric assay, related to clinical outcome (table 2), and then analysed statistically.
BIOCHEMISTRY
Cathepsin D concentrations were measured in 270 deep frozen tumour cytosols (-70°C) which had been prepared for steroid hormone receptor determination between 1983 and 1988. However, in one case the amount of cytosol remaining was insufficient for cathepsin D measurement. The tumour tissues used for cytosol extraction and for immunohistochemistry, respectively, were adjacent parts of the same tumour sample. Tissue processing and cytosol extraction were performed according to the EORTC guidelines.32
Cathepsin D concentrations in cytosols were measured by an immunoradiometric assay (ELSA-CATH-D, Isotopen Diagnostik CIS) using a monoclonal antibody that recognises 52 kDa procathepsin D and its 48 kDa and 34 kDa secretion products. Cathepsin D concentrations (fmol/ml) were related to cytosol protein concentrations (0-9-10-4 mg/ml) measured according to Lowry et al, 33 and recorded in pmol/mg. The minimum detection limit of the assay was 200-300 fmol/ml. The recovery rate ranged from 96% to 109% (540-2540 fmol/ml). The coefficients of the intra-assay (n = 4 assays, 21-103 pmol/mg) and interassay variance (n = 13 assays, pmol/mg) were 3 8% and 10 1%, respectively. A cathepsin D cytosol concentration of 40 pmol/mg was taken as the cut off limit.5 STATISTICS Statistical analyses were performed using the software SPSS 5.0.2 for windows (Statistical Package for the Social Sciences; Munich). The Spearman rank test was used for comparison of the immunohistochemical and immuno- Table 3 Correlation between classic prognostic factors and immunohistochemical cathepsin D detection (evaluation formula ES) for the total study group and node negative and node positive sub-groups shown to increase survival39 but may cause severe side effects, is always a challenging decision whereby the risk of overtreatment must be weighed against the probable benefits to certain patients. 
